Quintas-Cardama et al. also showed significantly higher JAK2V617F response rates to IFN in TET2 wild type patients in contrast to TET2 mutated patients [198], whereas Kralovics et al. reported no significant difference in response rates during ropeginterferon-alpha2b in their NGS study of 163 PV patients [182]. The gene discussed is TET2; the disease is acquired polycythemia vera.